Suchergebnisse - "Richardson, Paul G"

PubPharm (14)

1

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition

enthalten in: Cancer research | 2014

von Mimura, N. | Hideshima, T. | Shimomura, T. | +15

2

Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

enthalten in: Cancer research | 2014

von Mimura, N. | Hideshima, T. | Shimomura, T. | +15

3

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235

enthalten in: Cancer research | 2009

von McMillin, D. | Ooi, M. | Delmore, J. | +11

4

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase-Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

enthalten in: Cancer research | 2009

von Mcmillin, D. | Ooi, M. | Delmore, J. | +11

5

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

enthalten in: Cancer research | 2008

von Mitsiades, C. | Ocio, E. | Pandiella, A. | +18

6

Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

enthalten in: Cancer research | 2008

von Mitsiades, C. | Ocio, E. | Pandiella, A. | +16

7

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

enthalten in: Cancer research | 2005

von Yasui, H. | Hideshima, T. | Raje, N. | +14

8

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

enthalten in: Cancer research | 2004

von Podar, K. | Shringarpure, R. | Tai, Y. | +7

9

Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib

enthalten in: Cancer research | 2004

von Podar, K. | Shringarpure, R. | Tai, Y. | +6

10

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

enthalten in: Cancer research | 2003

von Hideshima, T. | Chauhan, D. | Hayashi, T. | +11